Lexington, United States
Humed Technologies, Inc. is a biotechnology and health care startup based in the United States. The company is dedicated to developing products that alleviate the adverse effects of cancer treatment, with a specific focus on addressing the painful mouth sores known as oral mucositis (OM).
OM affects a significant percentage of cancer patients, with 30-40% of the 1.8 million Americans diagnosed with cancer annually experiencing this condition. Additionally, 100% of head and neck cancer patients receiving altered fractionation radiation treatment suffer from OM, resulting in significant pain and treatment interruptions.
The company's first product, an innovative oral rinse, is expected to quickly enter the market with a 510(k) clearance in as soon as 22 months. This product stands out as the only mouthwash visibly showing surface coverage in the oral mucosa through the use of colored, patented technology, utilizing curcumin as a natural colorant.
Humed Technologies is addressing a critical need in a $500M market with a CAGR of ~8.0% over 5 years, aiming to improve patient and oncologist confidence while reducing compliance issues associated with existing barrier rinse products.
With 18 million cancer patients globally, and a significant percentage experiencing OM due to chemotherapy and radiation, the potential market for HuMed's products is substantial. The company's focus on addressing a pressing need in cancer care, combined with its innovative product development, positions it as a promising player in the biotechnology and health care sectors.